Insys Therapeutics (INRX) Files $55M IPO
Tweet
Share
E-mail
Insys Therapeutics, Inc. (Nasdaq: INRX) filed a registration statement with the U.S. Securities and Exchange Commission today for an Initial Public Offering of their Common Stock. The proposed maximum aggregate offering price is $55 million. The company has filed to list their shares on the Nasdaq Global Market under the ticker "INRX."
The offering is being made through Wells Fargo Securities, JMP Securities, and Oppenheimer & Co.
Insys Therapeutics is a specialty pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care.
The offering is being made through Wells Fargo Securities, JMP Securities, and Oppenheimer & Co.
Insys Therapeutics is a specialty pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ADARx IPO raises $602.5M after underwriters exercise full option
- Minerals Technologies prices $400M senior notes offering at 7.5%
- Axogen acquires BioCircuit, adding sutureless nerve repair device
Create E-mail Alert Related Categories
IPOsRelated Entities
JMP Securities, Wells FargoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
